^
Association details:
| Biomarker: | NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + emilumenib succinate (DS-1594) (Menin-MLL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Excerpt:
...Maximum tolerated dose (MTD) (Phase I)`Recommended phase 2 dose (RP2D) (Phase I)`Incidence of adverse events (Phase I)`Complete remission (CR) and complete remission with partial hematologic recover (CRh) rate with DS-1594b monotherapy in recurrent/refractory (R/R) acute myeloid leukemia (AML) with mixed-lineage leukemia rearrangement (MLLr) (Phase II, Cohort A)`CR/CRh rate with DS-1594b monotherapy in R/R AML with nucleophosmin 1 mutation (NPM1m) (Phase II, Cohort B)`CR+CRh rate of DS1594b in combination with azacitidine and venetoclax in R/R MLLr or R/R NPM1m AML (Phase II, Cohort C)`CR+CRh rate of DS1594b in combination with mini-HCVD in R/R ALL with MLLr (Phase II, Cohort D)`CR+ complete remission with incomplete hematologic recovery (CRi) rate of DS-1594b in combination with mini-HCVD in R/R ALL with MLLr...
Trial ID:
Source:
Title:
4169 Synergistic Growth Inhibition of NPM1 Mutant AML PDX By Combined Therapy with BCL-2 Inhibitor Venetoclax (ABT-199) and Menin Inhibitor DS-1594b In Vivo
Published date:
11/02/2023
Excerpt:
In the in vivo experiment with NPM1m PDX/luc/GFP AML PDX model, we found that co-treatment with DS-1594b and venetoclax for four weeks resulted in a greater reduction in AML burden compared to treatment with either agent alone or a vehicle control...The survival curve clearly demonstrated the benefits of the combination treatment, with the DS-1594b group having modest anti-tumor efficacy, and the combination group showing the greatest efficacy (Fig. 1A).
